1Q Preview: J&J, Roche, Novartis, Biogen
This article was originally published in Scrip
The big pharma first-quarter financial reporting season will be set in motion on April 19 by habitual early birds Roche and Johnson & Johnson.
You may also be interested in...
Results from two trials confirm patients at high risk of bleeding treated with Abbott’s Xience stent can be safely treated with short regimens of dual antiplatelet therapy.
Through a licensing-out deal with ORIC for its EGFR/HER2 exon-20 inhibitor, South Korea's Voronoi hopes to gain from its new partner's commercialization experience in NSCLC. The alliance hopes to build a potentially best-in-class presence in a competitive landscape.
An expert panel at the virtual HLTH conference discussed the role of robotics in improving health and wellness in the health continuum. See what Darla Hutton, vice president of US marketing and customer hospital analytics at Intuitive Surgical, said about the future of robotics.